Blar i forfatter Det helsevitenskapelige fakultet "Halvorsen, Bente"

Viser treff 1-14 av 14

    • Circulating markers of extracellular matrix remodelling in severe COVID-19 patients 

      Murphy, Sarah Louise Mikalsen; Halvorsen, Bente; Holter, Jan Cato; Huse, Camilla; Tveita, Anders; Trøseid, Marius; Hoel, Hedda; Kildal, Anders Benjamin; Holten, Aleksander Rygh; Lerum, Tøri Vigeland; Skjønsberg, Ole Henning; Michelsen, Annika Elisabet; Aaløkken, Trond Mogens; Tonby, Kristian; Lind, Andreas; Dudman, Susanne Gjeruldsen; Granerud, Beathe Kiland; Heggelund, Lars; Bøe, Simen; Dyrholt-Riise, Anne Ma; Aukrust, Pål; Barratt-Due, Andreas; Ueland, Thor; Dahl, Tuva Børresdatter (Journal article; Tidsskriftartikkel; Peer reviewed, 2023-09-17)
      Background Abnormal remodelling of the extracellular matrix (ECM) has generally been linked to pulmonary inflammation and fibrosis and may also play a role in the pathogenesis of severe COVID-19. To further elucidate the role of ECM remodelling and excessive fibrogenesis in severe COVID-19, we examined circulating levels of mediators involved in various aspects of these processes in COVID-19 ...

    • Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID‑19 (Bari‑SolidAct): a randomised, double‑blind, placebo‑controlled phase 3 trial 

      Trøseid, Marius; Arribas, José R.; Assoumou, Lambert; Holten, Aleksander Rygh; Poissy, Julien; Terzic, Vida; Mazzaferri, Fulvia; Baño, Jesús Rodríguez; Eustace, Joe; Hites, Maya; Joannidis, Michael; Paiva, José-Artur; Reuter, Jean; Püntmann, Isabel; Patrick-Brown, Thale Dawn; Westerheim, Elin; Nezvalova-Henriksen, Katerina; Beniguel, Lydie; Dahl, Tuva Børresdatter; Bouscambert, Maude; Halanova, Monika; Péterfi, Zoltán; Tsiodras, Sotirios; Rezek, Michael; Briel, Matthias; Ünal, Serhat; Schlegel, Martin; Ader, Florence; Lacombe, Karine; Amdal, Cecilie Delphin; Rodrigues, Serge; Tonby, Kristian; Gaudet, Alexandre; Heggelund, Lars; Mootien, Joy; Johannessen, Asgeir; Møller, Jannicke Horjen; Pollan, Beatriz Diaz; Tveita, Anders Aune; Kildal, Anders Benjamin; Richard, Jean-Christophe; Dalgard, Olav; Simensen, Victoria Charlotte; Baldé, Aliou; de Gastines, Lucie; del Álamo, Marta; Aydin, Burç; Lund-Johansen, Fridtjof; Trabaud, Mary-Anne; Diallo, Alpha; Halvorsen, Bente; Røttingen, John-Arne; Tacconelli, Evelina; Yazdanpanah, Yazdan; Olsen, Inge Christoffer; Costagliola, Dominique; Study Group, EU-SolidAct (Journal article; Tidsskriftartikkel; Peer reviewed, 2023-01-10)
      Background Baricitinib has shown efcacy in hospitalized patients with COVID-19, but no placebo-controlled trials have focused specifcally on severe/critical COVID, including vaccinated participants.<p> <p>Methods Bari-SolidAct is a phase-3, multicentre, randomised, double-blind, placebo-controlled trial, enrolling participants from June 3, 2021 to March 7, 2022, stopped prematurely for external ...

    • IL-6 receptor inhibition by tocilizumab attenuated expression of C5a receptor 1 and 2 in non-ST-elevation myocardial infarction 

      Orrem, Hilde Lang; Nilsson, Per; Pischke, Søren Erik; Kleveland, Ola; Yndestad, Arne; Ekholt, Karin; Damås, Jan Kristian; Espevik, Terje; Bendz, Bjørn; Halvorsen, Bente; Gregersen, Ida; Wiseth, Rune; Andersen, Geir Øystein; Ueland, Thor; Gullestad, Lars; Aukrust, Pål; Barratt-Due, Andreas; Mollnes, Tom Eirik (Journal article; Tidsskriftartikkel; Peer reviewed, 2018-09-12)
      <p><i>Background</i>: Elevated interleukin-6 (IL-6) and complement activation are associated with detrimental effects of inflammation in coronary artery disease (CAD). The complement anaphylatoxins C5a and C3a interact with their receptors; the highly inflammatory C5aR1, and the C5aR2 and C3aR. We evaluated the effect of the IL-6 receptor (IL-6R)-antagonist tocilizumab on the expression of the ...

    • Impaired HDL function amplifies systemic inflammation in common variable immunodeficiency 

      Macpherson, Magnhild Eide; Halvorsen, Bente; Yndestad, Arne; Ueland, Thor; Mollnes, Tom Eirik; Berge, Rolf Kristian; Rashidi, Azita; Otterdal, Kari; Gregersen, Ida; Kong, Xiang Yi; Holven, Kirsten Bjørklund; Aukrust, Pål; Fevang, Børre; Jørgensen, Silje Fjellgård (Journal article; Tidsskriftartikkel; Peer reviewed, 2019-07-01)
      Common variable immunodeficiency (CVID) is the most common symptomatic primary immunodeficiency, characterized by inadequate antibody responses and recurrent bacterial infections. Paradoxically, a majority of CVID patients have non-infectious inflammatory and autoimmune complications, associated with systemic immune activation. Our aim was to explore if HDL, known to have anti-inflammatory properties, ...

    • Increased Systemic and Local Interleukin 9 Levels in Patients with Carotid and Coronary Atherosclerosis 

      Gregersen, Ida; Skjelland, Mona; Holm, Sverre; Holven, Kirsten Bjørklund; Sørensen, Kirsten; Russell, David; Askevold, Erik Tandberg; Dahl, Christen Peder; Ørn, Stein; Gullestad, Lars; Mollnes, Tom Eirik; Ueland, Thor; Aukrust, Pål; Halvorsen, Bente (Journal article; Tidsskriftartikkel; Peer reviewed, 2013)
      Objective: Atherosclerosis is a chronic inflammatory disorder that involves a range of inflammatory mediators. Although interleukin (IL)-9 has been related to inflammation, there are at present no data on its role in atherosclerosis. Here we have examined IL-9 and IL-9 receptor (IL-9R) systemically and locally in patients with coronary and carotid atherosclerosis. Methods: Plasma IL-9 was quantified ...

    • Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1β in non-ST-elevation myocardial infarction 

      Kleveland, Ola; Ueland, Thor; Kunszt, Gabor; Bratlie, Marte; Yndestad, Arne; Broch, Kaspar; Holte, Espen; Ryan, Liv; Amundsen, Brage H.; Bendz, Bjørn; Aakhus, Svend; Espevik, Terje; Halvorsen, Bente; Mollnes, Tom Eirik; Wiseth, Rune; Gullestad, Lars; Aukrust, Pål; Damås, Jan Kristian (Journal article; Tidsskriftartikkel; Peer reviewed, 2018-06-29)
      <p><i>Aim</i>: To evaluate the effect of interleukin-6 inhibition with tocilizumab on the cytokine network in patients with acute non-ST-elevation myocardial infarction (NSTEMI).</p> <p><i>Methods</i>: 117 patients with acute NSTEMI were randomised to an intravenous infusion of 280 mg tocilizumab or placebo prior to coronary angiography. Blood samples were obtained at baseline, at 6 consecutive ...

    • Intestinal fatty acid binding protein is associated with cardiac function and gut dysbiosis in chronic heart failure 

      Nendl, Andraz; Raju, Sajan; Broch, Kaspar; Mayerhofer, Christiane Caroline; Holm, Kristian; Halvorsen, Bente; Lappegård, Knut Tore; Moscavitch, Samuel; Hov, Johannes Espolin Roksund; Seljeflot, Ingebjørg; Trøseid, Marius; Awoyemi, Ayodeji Olawale (Journal article; Tidsskriftartikkel; Peer reviewed, 2023-06-02)
      Background: The gut microbiota in patients with chronic heart failure (HF) is characterized by low bacterial diversity and reduced ability to synthesize beneficial metabolites. These changes may facilitate leakage of whole bacteria or bacterial products from the gut into the bloodstream, which may activate the innate immune system and contribute to the low-grade inflammation seen in HF. In this ...

    • LIGHT/TNFSF14 is increased in patients with type 2 diabetes mellitus and promotes islet cell dysfunction and endothelial cell inflammation in vitro 

      Halvorsen, Bente; Santilli, Francesca; Scholz, Hanne; Sahraoui, Afaf; Gulseth, Hanne Løvdal; Wium, Cecilie; Lattanzio, Stefano; Formoso, Gloria; Di Fulvio, Patrizia; Otterdal, Kari; Retterstøl, Kjetil; Holven, Kirsten Bjørklund; Gregersen, Ida; Stavik, Benedicte; Bjerkeli, Vigdis; Michelsen, Annika; Ueland, Thor; Liani, Rossella; Davi, Giovanni; Aukrust, Pål (Journal article; Tidsskriftartikkel; Peer reviewed, 2016-07-15)
      Aims/hypothesis: Activation of inflammatory pathways is involved in the pathogenesis of type 2 diabetes mellitus. On the basis of its role in vascular inflammation and in metabolic disorders, we hypothesised that the TNF superfamily (TNFSF) member 14 (LIGHT/TNFSF14) could be involved in the pathogenesis of type 2 diabetes mellitus. <p>Methods: Plasma levels of LIGHT were measured in two cohorts of ...

    • Markers of extracellular matrix remodeling and systemic inflammation in patients with heritable thoracic aortic diseases 

      Seim, Bjørn Edvard; Holt, Margrethe Flesvig; Ratajska, Aleksandra; Michelsen, Annika Elisabet; Ringseth, Monica Myklebust; Halvorsen, Bente; Skjelland, Mona; Kvitting, John-Peder; Lundblad, Runar; Krohg-Sørensen, Kirsten; Osnes, Liv T. N.; Aukrust, Pål; Paus, Benedicte; Ueland, Thor (Journal article; Tidsskriftartikkel; Peer reviewed, 2022-12-20)
      Background: In approximately 20% of patients with thoracic aortic aneurysms or dissections a heritable thoracic aortic disease (HTAD) is suspected. Several monogenic connective tissue diseases imply high risk of aortic disease, including both non-syndromic and syndromic forms. There are some studies assessing inflammation and extracellular matrix remodeling in patients with non-hereditary aortic ...

    • Prediction of underlying atrial fibrillation in patients with a cryptogenic stroke: results from the NOR-FIB Study 

      Ratajczak-Tretel, Barbara; Lambert, Anna Tancin; Al-Ani, Riadh Ibrahim Mahmud; Arntzen, Kathrine Grønning; Bakkejord, Grete; Bekkeseth, Hanna Marie Otterholt; Bjerkeli, Vigdis; Eldøen, Guttorm; Gulsvik, Anne Kristine; Halvorsen, Bente; Høie, Gudrun; Ihle-Hansen, Hege Beathe; Ihle-Hansen, Håkon; Ingebrigtsen, Susanne; Kremer, C.; Krogseth, Siv Bohne; Kruuse, C.; Kurz, Martin; Nakstad, Ingvild; Novotny, Vojtech; Næss, Halvor; Qazi, Rehman Ul-Haq; Rezaj, M.K.; Rørholt, Dag Marius Nitschke; Steffensen, Linn Hofsøy; Sømark, Jesper Norsted; Tobro, Håkon; Truelsen, T.C.; Wassvik, L.; Ægidius, K.L.; Atar, Dan; Aamodt, Anne Hege (Journal article; Tidsskriftartikkel; Peer reviewed, 2023-05-10)
      Background - Atrial fibrillation (AF) detection and treatment are key elements to reduce recurrence risk in cryptogenic stroke (CS) with underlying arrhythmia. The purpose of the present study was to assess the predictors of AF in CS and the utility of existing AF-predicting scores in The Nordic Atrial Fibrillation and Stroke (NOR-FIB) Study.<p> <p>Method - The NOR-FIB study was an international ...

    • Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma 

      Nyakas, Marta Sølvi; Aamdal, Elin; Jacobsen, Kari Dolven; Guren, Tormod Kyrre; Aamdal, Steinar; Hagene, Kirsten Thorin; Brunsvig, Paal Fr.; Yndestad, Arne; Halvorsen, Bente; Tasken, Kristin Austlid; Aukrust, Pål; Mælandsmo, Gunhild Mari; Ueland, Thor (Journal article; Tidsskriftartikkel; Peer reviewed, 2019-03-01)
      New therapies, including the anti‐cytotoxic T lymphocyte antigen (CTLA)‐4 antibody, ipilimumab, is approved for metastatic melanoma. Prognostic biomarkers need to be identified, because the treatment has serious side effects. Serum samples were obtained before and during treatment from 56 patients with metastatic or unresectable malignant melanoma, receiving treatment with ipilimumab in a national ...

    • Rifaximin or Saccharomyces boulardii in heart failure with reduced ejection fraction: Results from the randomized GutHeart trial 

      Awoyemi, Ayodeji Olawale; Mayerhofer, Cristiane; Felix, Alex S.; Hov, Johannes Espolin Roksund; Moscavitch, Samuel D.; Lappegård, Knut Tore; Hovland, Anders; Halvorsen, Sigrun; Halvorsen, Bente; Gregersen, Ida; Svardal, Asbjørn M.; Berge, Rolf Kristian; Hansen, Simen Hyll; Götz, Alexandra; Holm, Kristian; Aukrust, Pål; Åkra, Sissel; Seljeflot, Ingebjørg; Solheim, Svein; Lorenzo, Andrea; Gullestad, Lars; Trøseid, Marius; Broch, Kaspar (Journal article; Tidsskriftartikkel; Peer reviewed, 2021-07-28)
      Background - The gut microbiota represents a potential treatment target in heart failure (HF) through microbial metabolites such as trimethylamine N-oxide (TMAO) and systemic inflammation. Treatment with the probiotic yeast Saccharomyces boulardii have been suggested to improve left ventricular ejection fraction (LVEF).<p> <p>Methods - In a multicentre, prospective randomized open label, blinded ...

    • Serum levels of inflammation-related markers and metabolites predict response to neoadjuvant chemotherapy with and without bevacizumab in breast cancers 

      Nome, Marianne Eikhom; Euceda, Leslie R.; Jabeen, Shakila; Debik, Julia; Bathen, Tone Frost; Giskeødegård, Guro F.; Tasken, Kristin Austlid; Mælandsmo, Gunhild Mari; Halvorsen, Bente; Yndestad, Arne; Borgen, Elin; Garred, Øystein; Aukrust, Pål; Ueland, Thor; Engebraaten, Olav; Kristensen, Vessela N.; Tekpli, Xavier (Journal article; Tidsskriftartikkel; Peer reviewed, 2019-08-24)
      Angiogenesis is necessary for tumor growth and has been targeted in breast cancer; however, it is unclear which patients will respond and benefit from antiangiogenic therapy. We report noninvasive monitoring of patient response to neoadjuvant chemotherapy given alone or in combination with anti‐vascular endothelial growth factor (bevacizumab) in a randomized clinical trial. At four time points during ...

    • Serum PCSK9 is modified by interleukin-6 receptor antagonism in patients with hypercholesterolaemia following non-ST-elevation myocardial infarction 

      Ueland, Thor; Kleveland, Ola; Michelsen, Annika; Wiseth, Rune; Damås, Jan Kristian; Aukrust, Pål; Gullestad, Lars; Halvorsen, Bente; Yndestad, Arne (Journal article; Tidsskriftartikkel; Peer reviewed, 2018-09-18)
      <p><i>Objective</i>: It is unclear if activation of inflammatory pathways regulates proprotein convertase subtilisin-kexin type 9 (PCSK9) levels.</p> <p><i>Approach</i>: We evaluated (1) the temporal course of serum PCSK9 during hospitalisation following acute coronary syndrome and associations with markers of inflammation (leucocyte counts, interleukin (IL)-6, C-reactive protein) and lipid levels ...